Headlines about Neuroderm (NASDAQ:NDRM) have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neuroderm earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.5012945869434 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Neuroderm (NASDAQ:NDRM) opened at $38.85 on Wednesday. Neuroderm has a 12 month low of $15.20 and a 12 month high of $38.95.
Separately, Zacks Investment Research lowered Neuroderm from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Neuroderm has a consensus rating of “Buy” and a consensus price target of $45.86.
COPYRIGHT VIOLATION NOTICE: “Neuroderm (NDRM) Given News Impact Score of 0.20” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/13/neuroderm-ndrm-given-news-impact-score-of-0-20.html.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for Neuroderm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuroderm and related companies with MarketBeat.com's FREE daily email newsletter.